A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
A clinical phase I dose-finding design with adaptive shrinking boundaries for drug combination trials
Abstract Background Combinations of drugs are becoming increasingly common in oncology treatment. In some cases, patients can benefit from the interaction between two drugs, although there is usually a higher risk of developing toxicity. Due to drug–drug interactions, multidrug combinations often exhibit different toxicity profiles than those of single drugs, …